Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 13/20 | 0.37 |
| ▸ | NR3C2 | P08235 | 12/20 | 0.37 |
| ▸ | PGR | P06401 | 5/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5644409 | 0.79 | NR3C1 (0.36) | NR3C1NR3C2PGRSLC6A2SLC6A4 | |
| SCHEMBL803635 | 0.78 | PTGS1 (0.39) | NR3C1NR3C2PGRSLC6A4HSD11B1 | |
| SCHEMBL5642171 | 0.78 | SLC6A2 (0.40) | NR3C1NR3C2PGRSLC6A2SLC6A4 | |
| SCHEMBL2814842 | 0.78 | CYP3A4 (0.43) | NOTUM | |
| SCHEMBL19924965 | 0.77 | KCNN4 (0.37) | SLC6A2SLC6A4AR | |
| SCHEMBL29700966 | 0.77 | KCNN4 (0.37) | SLC6A2SLC6A4AR | |
| SCHEMBL17162836 | 0.75 | MAPT (0.36) | PGRSLC6A4AR | |
| SCHEMBL31445000 | 0.75 | NR3C1 (0.47) | NR3C1NR3C2PGR | |
| SCHEMBL16579371 | 0.75 | NR3C1 (0.35) | NR3C1NR3C2PGRSLC6A4HSD11B1 | |
| SCHEMBL4573201 | 0.74 | AR (0.38) | SLC6A4HSD11B1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1915231-A | Use of nonsteroidal in preparing drug of antiinflammatory agents | SCHERING AG (DE) | 2007-02-21 | — | — | CN | disclosed |
| US-7166592-B2 | Antiinflammatory agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-01-23 | — | — | US | disclosed |
| US-7129270-B2 | Nonsteroidal antiinflammatory agents | Schėring AG (DE) | 2006-10-31 | — | — | US | disclosed |
| US-20060040933-A1 | Nonsteroidal antiinflammatory agents | JAROCH STEFAN | 2006-02-23 | — | — | US | disclosed |
| US-20040254249-A1 | Nonsteroidal antiinflammatory agents | JAROCH STEFAN (DE) | 2004-12-16 | — | — | US | disclosed |
| US-6777409-B2 | FOR THERAPY OF INFLAMMATION | SCHERING AKTIENGESELLSCHAFT PATENTS (DE) | 2004-08-17 | — | — | US | disclosed |
| CN-1444570-A | Non-steroidal anti-inflammatory drugs | SCHERING AG (DE) | 2003-09-24 | — | — | CN | disclosed |
| EP-1309571-A1 | NON-STEROIDAL INFLAMMATION INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-05-14 | — | — | EP | disclosed |
| US-20020077356-A1 | Nonsteroidal antiinflammatory agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-06-20 | — | — | US | disclosed |
| WO-2002010143-A1 | NON-STEROIDAL INFLAMMATION INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077356-A1 | Nonsteroidal antiinflammatory agents | PTGS1, PTGES2, PTGES | NR3C1 98/4885NR3C2 155/4885PGR 1776/4885 |
| US-20060040933-A1 | Nonsteroidal antiinflammatory agents | PTGES, PTGES2, PTGS1 | NR3C1 150/4885NR3C2 156/4885PGR 1229/4885 |
| US-20040254249-A1 | Nonsteroidal antiinflammatory agents | PTGS1, PTGER1, PTGES2 | NR3C1 135/4885NR3C2 255/4885PGR 2398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.